Boothbay Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Boothbay Fund Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.23M	Buy	156,612 +14,634	+10%	+$363K	0.07%	338
2026 Q1	$2.97M	Buy	+141,978	New	+$3.2M	0.04%	480
2025 Q4	–	Sell	-46,269	Closed	-$1.52M	–	2282
2025 Q3	$1.39M	Buy	46,269 +34,775	+303%	+$1.04M	0.02%	699
2025 Q2	$418K	Sell	11,494 -54,161	-82%	-$1.95M	0.01%	978
2025 Q1	$2.38M	Buy	65,655 +11,200	+21%	+$466K	0.06%	389
2024 Q4	$2.29M	Sell	54,455 -11	-0%	-$546	0.06%	414
2024 Q3	$3.03M	Buy	+54,466	New	+$2.77M	0.07%	393
2023 Q4	–	Sell	-37,591	Closed	-$1.34M	–	1917
2023 Q3	$1.34M	Buy	37,591 +12,797	+52%	+$507K	0.03%	637
2023 Q2	$1.14M	Buy	+24,794	New	+$1.15M	0.03%	775
2020 Q1	–	Sell	-8,289	Closed	-$430K	–	1019
2019 Q4	$354K	Buy	+8,289	New	+$342K	0.03%	573

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Boothbay Fund Management's RARE Position: Q2 2026 in Review

Boothbay Fund Management increased its Ultragenyx Pharmaceutical (RARE) stake by 10% in Q2 2026, buying an estimated $363K and bringing the position to 156,612 shares worth $5.23M. The position accounts for 0.07% of the portfolio, ranked #338.

Boothbay Fund Management first reported a position in RARE in Q4 2019 and has held it in 10 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Boothbay Fund Management held 156,612 shares of Ultragenyx Pharmaceutical worth $5.23M as of Q2 2026.
Boothbay Fund Management bought 14,634 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $363K.
Ultragenyx Pharmaceutical made up 0.07% of Boothbay Fund Management's portfolio in Q2 2026, its #338 holding.
Boothbay Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 10 quarters since.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.